Inhibition of EGFR Signaling and Activation of Mitochondrial Apoptosis Contribute to Tanshinone IIA-Mediated Tumor Suppression in Non-Small Cell Lung Cancer Cells

References

• Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–454. doi:10.1038/nature2518329364287
   PubMed Web of Science ®Google Scholar
• Skoulidis F, Heymach JV. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer. 2019;19(9):495–509. doi:10.1038/s41568-019-0179-831406302
   PubMed Web of Science ®Google Scholar
• Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. JAMA. 2019;322(8):764–774. doi:10.1001/jama.2019.1105831454018
   PubMed Web of Science ®Google Scholar
• Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121(9):725–737. doi:10.1038/s41416-019-0573-831564718
   PubMed Web of Science ®Google Scholar
• Santoni-Rugiu E, Melchior LC, Urbanska EM, et al. Intrinsic resistance to EGFR-Tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: differences and similarities with acquired resistance. Cancers (Basel). 2019;11(7):923. doi:10.3390/cancers11070923
   PubMed Web of Science ®Google Scholar
• Wu SG, Shih JY. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018;17(1):38. doi:10.1186/s12943-018-0777-129455650
   PubMed Web of Science ®Google Scholar
• Lim SM, Syn NL, Cho BC, Soo RA. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: mechanisms and therapeutic strategies. Cancer Treat Rev. 2018;65:1–10. doi:10.1016/j.ctrv.2018.02.00629477930
   PubMed Web of Science ®Google Scholar
• Zhang Y, Jiang P, Ye M, Kim SH, Jiang C, Lu J. Tanshinones: sources, pharmacokinetics and anti-cancer activities. Int J Mol Sci. 2012;13(10):13621–13666. doi:10.3390/ijms13101362123202971
   PubMed Web of Science ®Google Scholar
• Chen Z, Xu H. Anti-inflammatory and immunomodulatory mechanism of tanshinone IIA for atherosclerosis. Evid Based Complement Alternat Med. 2014;2014:267976. doi:10.1155/2014/26797625525444
   PubMed Web of Science ®Google Scholar
• Ma L, Jiang H, Xu X, et al. Tanshinone IIA mediates SMAD7-YAP interaction to inhibit liver cancer growth by inactivating the transforming growth factor beta signaling pathway. Aging (Albany NY). 2019;11(21):9719–9737. doi:10.18632/aging.v11i2131711043
   PubMedGoogle Scholar
• Wang M, Zeng X, Li S, et al. A novel tanshinone analog exerts anti-cancer effects in prostate cancer by inducing cell apoptosis, arresting cell cycle at G2 Phase and blocking metastatic ability. Int J Mol Sci. 2019;20(18):4459.
   PubMed Web of Science ®Google Scholar
• Li K, Liu W, Zhao Q, et al. Combination of tanshinone IIA and doxorubicin possesses synergism and attenuation effects on doxorubicin in the treatment of breast cancer. Phytother Res. 2019;33(6):1658–1669. doi:10.1002/ptr.v33.630945389
   PubMed Web of Science ®Google Scholar
• Xue J, Jin X, Wan X, et al. Effects and MECHANISM OF TANSHINONE II a in proliferation, apoptosis, and migration of human colon cancer cells. Med Sci Monit. 2019;25:4793–4800. doi:10.12659/MSM.91444631250836
   PubMed Web of Science ®Google Scholar
• Wang R, Luo Z, Zhang H, Wang T. Tanshinone IIA reverses gefitinib-resistance in human non-small-cell lung cancer via regulation of VEGFR/Akt pathway. Onco Targets Ther. 2019;12:9355–9365. doi:10.2147/OTT.S22122831807016
   PubMed Web of Science ®Google Scholar
• Luo H, Vong CT, Chen H, et al. Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine. Chin Med. 2019;14:48.31719837
   PubMed Web of Science ®Google Scholar
• Xu S, Liu P. Tanshinone II-A: new perspectives for old remedies. Expert Opin Ther Pat. 2013;23(2):149–153. doi:10.1517/13543776.2013.74399523231009
   PubMed Web of Science ®Google Scholar
• Bai Y, Zhang L, Fang X, Yang Y. Tanshinone IIA enhances chemosensitivity of colon cancer cells by suppressing nuclear factor-kappaB. Exp Ther Med. 2016;11(3):1085–1089. doi:10.3892/etm.2016.298426998041
   PubMed Web of Science ®Google Scholar
• Lv C, Zeng HW, Wang JX, et al. The antitumor natural product tanshinone IIA inhibits protein kinase C and acts synergistically with 17-AAG. Cell Death Dis. 2018;9(2):165. doi:10.1038/s41419-017-0247-529416003
   PubMedGoogle Scholar
• Guo Y, Li Y, Wang FF, et al. The combination of Nutlin-3 and Tanshinone IIA promotes synergistic cytotoxicity in acute leukemic cells expressing wild-type p53 by co-regulating MDM2-P53 and the AKT/mTOR pathway. Int J Biochem Cell Biol. 2019;106:8–20. doi:10.1016/j.biocel.2018.10.00830389549
   PubMed Web of Science ®Google Scholar
• Zhou L, Yu X, Li M, et al. Cdh1-mediated Skp2 degradation by dioscin reprogrammes aerobic glycolysis and inhibits colorectal cancer cells growth. EBioMedicine. 2019;51:102570.31806563
   PubMed Web of Science ®Google Scholar
• Liu W, Li W, Liu H, Yu X. Xanthohumol inhibits colorectal cancer cells via downregulation of Hexokinases II-mediated glycolysis. Int J Biol Sci. 2019;15(11):2497–2508. doi:10.7150/ijbs.3748131595166
   PubMed Web of Science ®Google Scholar
• Yu X, Wang R, Zhang Y, et al. Skp2-mediated ubiquitination and mitochondrial localization of Akt drive tumor growth and chemoresistance to cisplatin. Oncogene. 2019;38(50):7457–7472. doi:10.1038/s41388-019-0955-731435020
   PubMed Web of Science ®Google Scholar
• Liu H, Li W, Yu X, et al. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis. Oncotarget. 2016;7(35):56338–56354. doi:10.18632/oncotarget.1084127472460
   PubMedGoogle Scholar
• Inuzuka H, Shaik S, Onoyama I, et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature. 2011;471(7336):104–109. doi:10.1038/nature0973221368833
   PubMed Web of Science ®Google Scholar
• Tucker WS, Kirsch WM, Martinez-Hernandez A, Fink LM. In vitro plasminogen activator activity in human brain tumors. Cancer Res. 1978;38(2):297–302.620402
   PubMed Web of Science ®Google Scholar
• De Ruysscher D, Faivre-Finn C, Nackaerts K, et al. Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer. Ann Oncol. 2020;31(1):41–49. doi:10.1016/j.annonc.2019.10.00331912794
   PubMed Web of Science ®Google Scholar
• Guo Y, Cao R, Zhang X, et al. Recent progress in rare oncogenic drivers and targeted therapy for non-small cell lung cancer. Onco Targets Ther. 2019;12:10343–10360. doi:10.2147/OTT.S23030931819518
   PubMed Web of Science ®Google Scholar
• Yuan M, Huang LL, Chen JH, Wu J, Xu Q. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther. 2019;4:61. doi:10.1038/s41392-019-0099-931871778
   PubMed Web of Science ®Google Scholar
• Gao J, HR L, Jin C, Jiang JH, Ding JY. Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer. Clin Transl Oncol. 2019;21(10):1287–1301. doi:10.1007/s12094-019-02075-130864018
   PubMed Web of Science ®Google Scholar
• Shi MJ, Dong BS, Yang WN, Su SB, Zhang H. Preventive and therapeutic role of Tanshinone A in hepatology. Biomed Pharmacother. 2019;112:108676. doi:10.1016/j.biopha.2019.10867630797157
   PubMed Web of Science ®Google Scholar
• Zhou ZY, Zhao WR, Zhang J, Chen XL, Tang JY. Sodium tanshinone IIA sulfonate: a review of pharmacological activity and pharmacokinetics. Biomed Pharmacother. 2019;118:109362. doi:10.1016/j.biopha.2019.10936231545252
   PubMed Web of Science ®Google Scholar
• Liao XZ, Gao Y, Huang S, et al. Tanshinone IIA combined with cisplatin synergistically inhibits non-small-cell lung cancer in vitro and in vivo via down-regulating the phosphatidylinositol 3-kinase/Akt signalling pathway. Phytother Res. 2019;33(9):2298–2309. doi:10.1002/ptr.639231268205
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang J, Jiang JY, Liu SD, Fu K, Liu HY. Tanshinone IIA induces cytochrome c-mediated caspase cascade apoptosis in A549 human lung cancer cells via the JNK pathway. Int J Oncol. 2014;45(2):683–690. doi:10.3892/ijo.2014.247124888720
   PubMed Web of Science ®Google Scholar
• Shi P, Oh YT, Deng L, et al. Overcoming acquired resistance to AZD9291, a third-generation EGFR inhibitor, through modulation of MEK/ERK-dependent bim and Mcl-1 degradation. Clin Cancer Res. 2017;23(21):6567–6579. doi:10.1158/1078-0432.CCR-17-157428765329
   PubMed Web of Science ®Google Scholar
• Ye M, Zhang Y, Zhang X, et al. Targeting FBW7 as a strategy to overcome resistance to targeted therapy in non-small cell lung cancer. Cancer Res. 2017;77(13):3527–3539. doi:10.1158/0008-5472.CAN-16-347028522751
   PubMed Web of Science ®Google Scholar
• Arai S, Jonas O, Whitman MA, Corey E, Balk SP, Chen S. Tyrosine kinase inhibitors increase MCL1 degradation and in combination with BCLXL/BCL2 inhibitors drive prostate cancer apoptosis. Clin Cancer Res. 2018;24(21):5458–5470. doi:10.1158/1078-0432.CCR-18-054930021909
   PubMed Web of Science ®Google Scholar
• Nalluri S, Peirce SK, Tanos R, et al. EGFR signaling defines Mcl(-)1 survival dependency in neuroblastoma. Cancer Biol Ther. 2015;16(2):276–286. doi:10.1080/15384047.2014.100233325756510
   PubMed Web of Science ®Google Scholar
• Tong J, Tan S, Zou F, Yu J, Zhang L. FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation. Oncogene. 2017;36(6):787–796. doi:10.1038/onc.2016.24727399335
   PubMed Web of Science ®Google Scholar
• Ding Q, He X, Hsu JM, et al. Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol. 2007;27(11):4006–4017. doi:10.1128/MCB.00620-0617387146
   PubMed Web of Science ®Google Scholar
• Trivigno D, Essmann F, Huber SM, Rudner J. Deubiquitinase USP9x confers radioresistance through stabilization of Mcl-1. Neoplasia. 2012;14(10):893–904. doi:10.1593/neo.1259823097624
   PubMed Web of Science ®Google Scholar
• Zhang S, Zhang M, Jing Y, et al. Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors. Nat Commun. 2018;9(1):215. doi:10.1038/s41467-017-02693-929335437
   PubMedGoogle Scholar